Get the Stockscreener App
1.26
1.56%
-0.02
Acrivon Therapeutics Inc stock is traded at $1.26, with a volume of 140.80K.
It is down -1.56% in the last 24 hours and up +2.44% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.28
Open:
$1.27
24h Volume:
140.80K
Relative Volume:
0.27
Market Cap:
$39.51M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.4532
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
-11.89%
1M Performance:
+2.44%
6M Performance:
-79.24%
1Y Performance:
-83.87%
1-Day Range:
$1.21
$1.2882
1-Week Range:
$1.21
$1.48
52-Week Range:
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.26 | 40.13M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Will breakout in Acrivon Therapeutics Inc. lead to full recoveryFree Risk Adjusted Technical Entry Plan - Newser
Statistical indicators supporting Acrivon Therapeutics Inc.’s strengthFree Accurate Technical Trend Reversal Picks - Newser
What moving averages say about Acrivon Therapeutics Inc.Weekly Chart Watchlist with Trade Guidance - Newser
Using economic indicators to assess Acrivon Therapeutics Inc. potentialFree Low Risk Picks for Daily Trading - Newser
Is Acrivon Therapeutics Inc. stock a good hedge against inflationPortfolio Safety Metrics and Return Analysis - Newser
What catalysts could drive Acrivon Therapeutics Inc. stock higher in 2025Retirement Planning Insights For 2025 - jammulinksnews.com
What is Acrivon Therapeutics Inc. company’s growth strategySmart Portfolio Data Feed For 2025 - jammulinksnews.com
Real time alert setup for Acrivon Therapeutics Inc. performanceFree Smart Money Tracking Signal Generator - Newser
Short interest data insights for Acrivon Therapeutics Inc.Value Investing Checklist with Entry Signals - Newser
Detecting support and resistance levels for Acrivon Therapeutics Inc.Smart Risk Entry Zone Technical Analysis - Newser
Applying big data sentiment scoring on Acrivon Therapeutics Inc.Free Optimized Watchlist With Daily Adjustments - Newser
Relative strength of Acrivon Therapeutics Inc. in sector analysisSafe Entry Zone Based on Chart Analysis - Newser
What makes Acrivon Therapeutics Inc. stock price move sharplyFree Investment Strategy With Predictable Gains - Newser
How Acrivon Therapeutics Inc. stock performs during market volatilityIntraday Movement Recap and Chart Summary - Newser
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionProfit Focused Stock Screener Results Released - beatles.ru
Historical volatility pattern of Acrivon Therapeutics Inc. visualizedFree Value Investing Picks With Stability - Newser
How high can Acrivon Therapeutics Inc. stock price go in 2025Free Capital Efficiency Optimized Stock Alerts - Newser
What are the technical indicators suggesting about Acrivon Therapeutics Inc.Post Market Target Finder For Every Investor - jammulinksnews.com
What is the dividend policy of Acrivon Therapeutics Inc. stockInvest confidently with professional advice - jammulinksnews.com
What are Acrivon Therapeutics Inc. company’s key revenue driversUnmatched market performance - jammulinksnews.com
Is Acrivon Therapeutics Inc. stock overvalued or undervaluedLow Risk Strategy With Low Risk - jammulinksnews.com
Historical volatility pattern of Acrivon Therapeutics Inc. visualized Free Step-by-Step Stock Investment Guide - Newser
How does Acrivon Therapeutics Inc. generate profit in a changing economyInvest confidently with real-time updates - jammulinksnews.com
Statistical indicators supporting Acrivon Therapeutics Inc.’s strength Safe and Scalable Return Strategy Blueprint - Newser
How strong is Acrivon Therapeutics Inc. company’s balance sheetMarket Forecast Data Feed Backed By Experts - jammulinksnews.com
When is Acrivon Therapeutics Inc. stock expected to show significant growthUnlock real-time stock alerts for quick profits - jammulinksnews.com
Should I hold or sell Acrivon Therapeutics Inc. stock in 2025Exceptional trading results - jammulinksnews.com
What institutional investors are buying Acrivon Therapeutics Inc. stockFastest-growing stock picks - jammulinksnews.com
What are the latest earnings results for Acrivon Therapeutics Inc.Capitalize on emerging market sectors - jammulinksnews.com
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):